The results showed an SMD of -0.07 U/L, (95% CI -0.31 to 0.17), P = 0.56 (Table 3) which demonstrates a non-significant decrease in the alanine aminotransferase among the Saroglitazar 4 mg/day group compared to the saroglitazar 2 mg/day group in patients with diabetes-related dyslipidemia (Table 3). Here, GPT is linked to metabolic syndrome.